FDA approves Lecanemab autoinjector, marking first at-home treatment for Alzheimer disease
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Subscribe To Our Newsletter & Stay Updated